Stocks and Investing Stocks and Investing
Tue, February 19, 2013
[ Tue, Feb 19th 2013 ] - Market Wire
BacTech Appoints New Director
[ Tue, Feb 19th 2013 ] - Market Wire
Investment in Great-West Lifeco
[ Tue, Feb 19th 2013 ] - Market Wire
Baristas Opens in Tempe by ASU
[ Tue, Feb 19th 2013 ] - Market Wire
It's All About Organization
[ Tue, Feb 19th 2013 ] - Market Wire
China Life Appoints New Auditor

Christopher Raymond Maintained (BMRN) at Buy with Increased Target to $64 on, Feb 19th, 2013


Published on 2024-10-25 01:57:44 - WOPRAI, Christopher Raymond
  Print publication without navigation


Christopher Raymond of Piper Sandler, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Buy with Increased Target from $55 to $64 on, Feb 19th, 2013.

Christopher has made no other calls on BMRN in the last 4 months.



There are 3 other peers that have a rating on BMRN. Out of the 3 peers that are also analyzing BMRN, 0 agree with Christopher's Rating of Hold.



These are the ratings of the 3 analyists that currently disagree with Christopher


  • Michelle Gilson of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $71 on, Tuesday, February 12th, 2013
  • Martin Auster of "UBS" Maintained at Strong Buy with Increased Target to $67 on, Friday, February 1st, 2013
  • Gena Wang of "Barclays" Maintained at Buy with Increased Target to $54 on, Tuesday, November 6th, 2012

Similar Stocks and Investing Articles